

Biotechnology 2019



Photo: © hywards - stock.adobe.com



Date of publication

28th September 2019

Copy Deadline

20th September 2019

Biotechnology 2019

Plattform Life Sciences | Issue 3/2019

The mission:

Providing a cross-channel connection between **Life Sciences** and the knowledge and networks of **corporate financing** and the **capital market**

Date of publication: 28th September 2019

Size of issue: approx. 140 pages

Copies to print: 7.000 copies; Digital distribution as free e-magazine

Language: German, English contributions are welcome

Expected distribution:

Trade fairs and conferences

- analytica, Munich
- Bio-Europe, Hamburg
- BioFIT, Marseille
- ECP, Frankfurt
- EFIB, Brussels
- ESIB, Graz
- Life Science Kongress, Heilbronn
- XPOMET & Frontiers Health, Berlin

Venture capital companies and their portfolio companies

Founders and participants in business plan competitions (e.g. Science4Life)

Subscribers of VentureCapital Magazine and Plattform Life Sciences

Listed companies and established non-listed companies



Cooperation with multipliers, associations and networks (e.g. BIO Deutschland, BPI, BVIZ, DIB, vfa bio)

Funding institutions (e.g. NRW.Bank)

Background and Objectives

The current EY report on Biotechnology in Germany defines the most important milestones for future success in the field of biotechnology: **Translation, entrepreneurial spirit and availability of capital**. It is nothing new that knowledge is the key to success. And indeed in the last decades considerable success has been achieved. Many German SMEs have been producing **positive figures**. Companies like Evotec, MorphoSys, Qiagen or Miltenyi show in an exemplary manner how entrepreneurial spirit and perseverance reveal **stories of success** originating in Germany.

In either case what is not disputed Germany stands for a **high excellence** in scientific research. University-based and extramural research institutes enjoy an outstanding reputation worldwide. But simultaneously the question is rising: Is biotechnology in Germany at an important **crossroads**? If you take a look on the expenses for **research & development** or **venture capital** the gap to the US seems to be unassailable. New competitors pull into the passing

lane: Critics fear that Europe and in particular Germany could miss the connection in comparison to Asia. Although the present situation does not seem to bring a rosy future, the basis is set and industry has become more mature.

In the 21st edition of the issue "Biotechnology" the editorial team is once more on the lookout for recent trends, newcomers, as well as potential "unicorns". They try to figure out which subsidies or capital resources could be tapped and which fruitful **partnerships between "Big Pharma" and Start-ups** might be thriving. This year's edition is complemented by success stories from science as well as young entrepreneurs **taking the plunge to the market or trading floor**.

Biotechnology is the key industry for mastering the challenges of the 21st century. Being a businessman, investor, consultant, or researcher, please take advantage of all the possibilities **Plattform Life Sciences** is offering. By presenting your view on things you can actively shape the future!

Main topics

- **100 years biotechnology**
- **Current trends in medical biotechnology:**
 - gene therapy vs. immunotherapy
 - AI in biotechnology
 - Comeback of neurology?
CNS diseases – great potential – great challenges
- **Biosimilars:**
Expiring patent protection pave the way for generics
- **Big Pharma and Biotech:**
What interests do corporates have?
Which hubs do start-ups find?
- **Industrial biotechnology and bio economy:**
Bio based resources – sustainability for the future?
- **Science and Research:**
Possibilities and challenges of a successful translation
- **Legal:**
Which risks does the usage of sensitive data constitute?
- **Case study:**
Success stories
- **Capital market and investment:**
Which stocks and funds are convincing?
How can investors profit from biotechnology?
- **Financing:**
Is the larger financing volume entirely rated positive?
Why is corporate VC booming?

Execution and Marketing

A. Partnerships:

On request

B. Adverts:

Booking can be made via the advertising department at GoingPublic Media AG, prices according to rate card, e.g. 1/1 page EUR 2,900, 1/2 page EUR 1,900, 1/3 page EUR 1,600.

C. Copy Sales:

In particular for the edition "Biotechnology", the publishers offer units of 100 copies for costs of production to be distributed to the main target groups, e.g. 500 copies at EUR 2.00 per copy, 1,000 copies at EUR 1.50 per copy (retail price EUR 12.50!). The publishers will gladly provide a detailed price scale upon request.

D. Special Advertising Format: "Profiles"

For companies, business promoters/cluster, investors, incubators, accelerators, technology centers, founder networks, business plan competitions, consultants, lawyers, and service providers: 1/2 page profile for just **EUR 950 plus VAT**,



incl. graphic design/layout. Moreover advertisers receive a short company description in our Life Sciences „Who is Who“ by ticketing a profile in one of our life sciences issues (www.goingpublic.de/who-is-who).

This could be your logo

Initial partners



大成 DENTONS



Contacts

Marketing:

Karin Hofelich, Publishing Director Life Sciences,
hofelich@goingpublic.de, phone: +49 (0) 89 – 2000 339-54

Nicole Unger, Business Development Management,
unger@goingpublic.de, phone: +49 (0) 89 – 2000 339-53

Editing:

Holger Garbs, Editor Life Sciences, Project leader,
garbs@goingpublic.de, mobile: +49 (0) 177-8821954

Falko Bozicevic, Editor in chief GoingPublic magazine,
fb@goingpublic.de, phone: +49 (0)69-74087-668,
mobile: +49 (0)177-4225289



Karin Hofelich



Nicole Unger



Holger Garbs



Falko Bozicevic

reply coupon

by Fax: +49 (0) 89 2000 339-0
 by E-Mail: hofelich@goingpublic.de
 unger@goingpublic.de

Date of Publication: 28th September 2019
Copy Deadline: 20th September 2019
Advertising close: 16th September 2019

Yes, we would like to join!

Advert, Format:

Profile Partner of the issue Advertorial

Price information

Advertising formats		
2/1 page		4.350 EUR
1/1 page		2.900 EUR
1/2 page		1.900 EUR
1/3 page		1.600 EUR
Profile		950 EUR
Partner of the issue		10.000 EUR
Other formats		On request!
NEW: Advertorial: 1/1 page (approx. 3.300 characters + illus.)		2.900 EUR
NEW: Advertorial: 2/1 page (approx. 7.300 characters + illus.)		4.350 EUR

All prices are additionally subject to value added tax 19%

We order _____ copies of the Special Edition „Biotechnology 2019“ for a subscription price of 9,80 EUR instead of EUR 12,50 (incl. 7% VAT, excl. EUR 1.80 for mailing)!

Company data or stamp

.....
 Company Name, Surname

.....
 Street Zip Code, City

.....
 E-Mail Telephone

.....
 Date/Signature